A
Alcista
Alcista · 25%NKTR
$0.66
Precio del escenario
$36.640
+0.879 (+2.40%)Al cierre
Loading chart…
- Máximo
- 36.790
- Apertura
- 36.000
- Precio medio ponderado por volumen
- 36.35
- Volumen
- 831.53K
- Capitalización
- 209.78M
- Mínimo
- 35.635
- Importe
- 30.23M
- EV/EBITDA, TTM
- -6.31
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials.
Análisis de IA of Nektar Therapeutics (NKTR)
VenderNektar Therapeutics is not a good buy right now due to its extremely low RSI of 16.77, indicating oversold conditions, and a significant 5-day price drop of 13.09%. Additionally, the stock's forward P/E ratio is high at 34.01, suggesting overvaluation relative to its earnings potential. The company faces legal risks and has seen a 1229.84% increase in hedge fund selling activity, which raises concerns about investor confidence.
Recomendaciones de analistas (11)
+236.87% de potencial alcista
Comprar
10 Comprar
1 Mantener
0 Vender
Actual: 36.64
Mínimo
102.00
Promedio
123.43
Máximo
165.00
Leerink
Superar al mercado
$130
2026-10-12
Leerink
2026-10-12
Precio objetivo
$130
Superar al mercado
UBS
Neutral
$53
2026-10-12
UBS
2026-10-12
Precio objetivo
$53
Neutral
Raymond James
Market Perform
—
2026-10-08
Raymond James
2026-10-08
Precio objetivo
—
Market Perform
Citi
Comprar
$151
2026-10-05
Citi
2026-10-05
Precio objetivo
$151
Comprar
H.C. Wainwright
Comprar
$185
2026-10-02
H.C. Wainwright
2026-10-02
Precio objetivo
$185
Comprar
Métricas de valoración
El PER previsto actual de Nektar Therapeutics (NKTR) es 34.01, frente a su media de 5 años de 3.05.
Escenarios de precio de Alphio AI para NKTR
Los precios por escenario son la última banda de previsión mensual del año en curso. Las probabilidades son pesos fijos del modelo (25 / 50 / 25), no garantías.
Ballenas con NKTR en cartera
Cronología de eventos
Noticias
9.510-01stocktwitsNektar's Therapy Data Triggers Stock Volatility
9.010-01PRnewswireRezpegaldesleukin Shows Significant Treatment Effects in Dermatological Conditions
9.010-01NewsfilterRezpegaldesleukin Shows Long-Term Efficacy in Alopecia Areata Treatment
9.009-30PRnewswireRezpegaldesleukin Shows Promising Results in Atopic Dermatitis
- 2.009-30Newsfilter
Rezpegaldesleukin Shows Early Efficacy in Atopic Dermatitis
Preguntas frecuentes sobre NKTR, respondidas por Alphio AI
Nektar Therapeutics is a clinical-stage biotechnology company. It is focused on developing treatments that address the underlying immunological dysfunction in autoimmune and chronic inflammatory diseases. In oncology, it is focused on developing medicines based on targeting biological pathways that stimulate and sustain the body’s immune response to fight cancer. Its lead product candidate, rezpegaldesleukin (REZPEG, or NKTR-358), is a novel regulatory T cell stimulator being evaluated in two Phase IIb clinical trials, one in atopic dermatitis and one in alopecia areata. Its pipeline also includes a preclinical bivalent tumor necrosis factor receptor type II (TNFR2) antibody and bispecific programs, NKTR-0165 and NKTR-0166, and a modified hematopoietic colony stimulating factor (CSF) protein, NKTR-422. It is also evaluating NKTR-255, an investigational IL-15 receptor agonist designed to boost the immune system's natural ability to fight cancer, in several ongoing clinical trials. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).
Nektar Therapeutics is not a good buy right now due to its extremely low RSI of 16.77, indicating oversold conditions, and a significant 5-day price drop of 13.09%. Additionally, the stock's forward P/E ratio is high at 34.01, suggesting overvaluation relative to its earnings potential. The company faces legal risks and has seen a 1229.84% increase in hedge fund selling activity, which raises concerns about investor confidence.
11 analysts cover NKTR: 10 rate it Buy, 1 Hold and 0 Sell. The average price target is 123.43.
Comunidad
Más ↗Aún no hay publicaciones
Regístrate o inicia sesión para participarEsta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.